Clinical trials: Barrett's Esophagus
Gastric Adenocarcinoma, Barrett Esophagus
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer.
- Trial name
- NCT00411151
- Testing
- Sunitinib-Malate
- Where
- 12 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Johannes Gutenberg University Mainz
Barrett's Esophagus
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
Barrett's esophagus can progress to esophageal cancer, but it doesn't always. Current treatment is frequent surveillance via upper endoscopy with multiple biopsies to look for changes (dysplasia).
- Trial name
- NCT00844077
- Where
- 6 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- University of Michigan
Barrett's Mucosa With High Grade Intraepithelial Neoplasia (HGIEN)
Confocal Laser Endomicroscopy and Endoscopic Mucosal Resection
The accurate detection and therapy of adenocarcinoma originating from Barrett's oesophagus is challenging as current endoscopic techniques are unreliable for both the detection of high grade intraepithelial neoplasia (HGIN)…
- Trial name
- NCT01124994
- Testing
- Endoscopic mucosal resection
- Where
- Austria
- Volunteers
- 38 people
- Sponsor
- Medical University of Vienna
Barrett's Esophagus
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
The specific aim of this study is to determine the feasibility of marking target pathologic locations identified on Optical Frequency Domain Imaging (OFDI) datasets using superficial cautery marks of the esophagus that are…
- Trial name
- NCT01439633
- Testing
- MGH OFDI marking
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Barrett Esophagus, Barretts Esophagus With Dysplasia
CLUE: CLinical Utility Study of EsoGuard
Utilize real-world data from the commercial use of EsoGuard testing on samples collected with EsoCheck (EC/EG) to evaluate the impact of EsoGuard results on health care provider's decision for endoscopy referral.
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma
- Trial name
- PR-0410 (NCT06030180)
- Testing
- EsoGuard
- Where
- 8 sites in United States
- Volunteers
- 566 people
- Sponsor
- Lucid Diagnostics, Inc.
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma.
- Conditions
- Superficial Esophageal Cancer, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Barretts Esophagus With Dysplasia
- Trial name
- FEO (NCT07343869)
- Where
- France
- Volunteers
- 750 people
- Sponsor
- Société Française d'Endoscopie Digestive
Barretts Esophagus With Dysplasia, Barrett Esophagus
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
The purpose of this study is to learn the best approach to treating patients with known or suspected Barrett's esophagus by comparing endoscopic surveillance to endoscopic eradication therapy.
- Conditions
- Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
- Trial name
- SURVENT (NCT05753748)
- Testing
- Endoscopic Eradication Therapy
- Where
- 30 sites in United States
- Volunteers
- 680 people
- Sponsor
- University of Colorado, Denver
Barrett's Esophagus
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
The purpose of this study is to determine the association between acid reflux and cell changes in Barrett's esophagus. Specific aim 1: To test the hypothesis that controlled acid reflux is associated with lesser degree of stromal…
- Trial name
- CR20 (NCT01281618)
- Testing
- 24 hour pH study and upper endoscopy (EGD)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Barrett's Esophagus, Esophageal Cancer
Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
The purpose of this study is to evaluate the treatment effect, depth of injury, and side effects using technology involving the spray of liquid nitrogen through a catheter (CryoSpray AblationTM, "CSA" or "cryospray therapy") onto…
- Trial name
- ESODOI (NCT00754468)
- Testing
- Cryo Spray Ablation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- CSA Medical, Inc.
Barrett Esophagus, Esophageal Adenocarcinoma
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- ESOGUARDBE2 (NCT04295811)
- Testing
- EsoGuard (lab assay), Esophagogastroduodenoscopy
- Where
- 35 sites in United States, Netherlands
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Lucid Diagnostics, Inc.
Barrett's Esophagus
Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium
The purpose of this study is to assess the efficacy and performance of the C2 Focal Cryoablation System in patients with BE.
- Trial name
- NCT02249975
- Testing
- C2 CryoBalloon Focal Ablation System
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Pentax Medical
Esophageal Cancer, Precancerous Condition
Erlotinib in Treating Patients With Barrett Esophagus
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00566800
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Kansas City Veteran Affairs Medical Center
Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia
Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)
This is a prospective randomized clinical trial examining how IRIS (Intelligent Real-time Image Segmentation) affects biopsy patterns in VLE (Volumetric laser endomicroscopy).
- Conditions
- Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia, Barrett's Esophagus With Low Grade Dysplasia, Barrett's Esophagus With High Grade Dysplasia
- Trial name
- NCT03814824
- Testing
- IRIS (Intelligent real-time image segmentation), VLE (Volumetric laser endomicroscopy)
- Where
- 3 sites in United States
- Volunteers
- 148 people
- Sponsor
- Northwell Health
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross Over
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies.
- Trial name
- NCT00637988
- Testing
- Esomeprazole, Aspirin, Rofecoxib
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Barrett Esophagus, Esophageal Cancer
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
To develop and endoscopic Raman spectroscopy probe for delivery down and channel in an endoscope to make near instant assessments of the condition of the oesophagus without the need for expensive and distressing tissue removal…
- Trial name
- RaPIDE (NCT03468634)
- Testing
- endoscopy
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Barrett Esophagus
Predict Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia
Researchers are trying to see if the Nvision® Imaging System (VLE) can accurately determine the risk of recurrent Barrett's esophagus in patients with Barrett's esophagus which have been clear of disease.
- Trial name
- NCT03670134
- Testing
- The Nvision VLE Imaging System
- Sponsor
- Mayo Clinic
Barretts Esophagus, High Grade Dysplasia
Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus
This study is being done to determine if a new endoscope will help doctors identify pre-cancer or early cancer lesions in patients who have Barrett's esophagus.
- Conditions
- Barretts Esophagus, High Grade Dysplasia, Early Esophageal Adenocarcinoma
- Trial name
- ETMI (NCT00586989)
- Testing
- Upper endoscopy with biopsy
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Barretts Esophagus With Dysplasia, Barrett Adenocarcinoma
EMR Versus ESD for Barrett's Neoplasia
Rationale: The optimal technique for removal of visible dysplastic lesions in Barrett's esophagus remains controversial. Endoscopic mucosal resection (EMR) is safe, effective, easy to apply, and has been the most widely used…
- Conditions
- Barretts Esophagus With Dysplasia, Barrett Adenocarcinoma, Esophageal Cancer
- Trial name
- REMOVE-RCT (NCT05276791)
- Testing
- EMR, ESD
- Where
- 6 sites in Netherlands
- Volunteers
- 331 people
- Sponsor
- St. Antonius Hospital
Barrett's Esophagus, Esophageal Cancer
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
- Trial name
- NCT01293448
- Testing
- Cryoballoon Ablation
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Pentax Medical
Barrett Esophagus, Adenocarcinoma Esophagus
Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus
The purpose of this study is to assess lymph node metastasis rate, distant metastasis rate, disease-specific mortality, and overall mortality in patients with Barrett's related T1b and high risk T1a esophageal adenocarcinoma…
- Conditions
- Barrett Esophagus, Adenocarcinoma Esophagus, Submucosal Esophageal Adenocarcinoma, High-risk Mucosal Esophageal Adenocarcinoma
- Trial name
- NCT04818476
- Testing
- diagnostic endoscopic resection
- Where
- 16 sites in Australia, Belgium and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)